Cannabis Bioscience (CBIH) has submitted a new Notice of Intention to Participate in the federal administrative hearing concerning the proposed transfer of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
CBIH previously participated in the administrative process related to this proposed rulemaking. Following the renewal of the proceedings by the Drug Enforcement Administration, the Company seeks to reaffirm its position and provide a perspective focused on research, medicine, regulation, and public health.
For CBIH, this renewed participation reflects a commitment to bringing a science-driven perspective to the federal rescheduling conversation. The Company's position is supported by a scientific portfolio that includes 25 completed patent assets for cannabinoid-based medical formulations across neurological, psychiatric, oncological, metabolic, musculoskeletal, gastrointestinal, microbiome-related, and other therapeutic areas.
"The uncertainty surrounding marijuana policy extends beyond the cannabis industry and the stigma associated with adult use, reaching the broader economy, scientific research, medicine, and public trust," said Rosangel Andrades, MD, CBIH R&D Director. "When stigma drives the conversation, banks hesitate, investors step back, researchers face added obstacles, and clinical development becomes more difficult, creating commercial, scientific, regulatory, and human setbacks."
"Rescheduling should not be viewed as the elimination of controls, but as an opportunity to build a clearer, more scientific, and more organized framework," said Dante Picazo, Chief Executive Officer of CBIH.
For more information:
Cannabis Bioscience International Holdings
Email: [email protected]
cbih.net/
